iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

Single-dose IBIO-610 showed up to 98% inhibition of active Activin E sustained for eight weeks, supporting a differentiated long-acting antibody approach. The results are directionally encouraging for durability of target engagement, though they read as early efficacy/clinical validation rather than a definitive regulatory or commercialization milestone.

Analysis

Single-dose IBIO-610 showed up to 98% inhibition of active Activin E sustained for eight weeks, supporting a differentiated long-acting antibody approach. The results are directionally encouraging for durability of target engagement, though they read as early efficacy/clinical validation rather than a definitive regulatory or commercialization milestone.